Streetbeat News

XTLB

XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

Industry

Biotechnology

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Ovid Therapeutics shares dropped 65.7% after Takeda's Skyline study in Dravet syndrome missed its primary endpoint. Other notable stock movements include Interactive Strength, Mustang Bio, Allego, and Scinai Immunotherapeutics among gainers, and Aerovate Therapeutics, Kaival Brands Innovations, and Workhorse Group among losers.

Portfolio Pulse from Avi Kapoor

June 17, 2024 | 5:21 pm

Shares of Nurix Therapeutics (NRIX) surged 12.1% in pre-market trading following positive clinical trial results. Other notable pre-market movers include Scinai Immunotherapeutics (SCNI), Interactive Strength (TRNR), ENDRA Life Sciences (NDRA), and The Aaron’s Company (AAN), which saw significant gains. Conversely, Ovid Therapeutics (OVID) and Kaival Brands Innovations (KAVL) experienced substantial declines.

Portfolio Pulse from Avi Kapoor

June 17, 2024 | 12:43 pm

XTL Biopharmaceuticals has entered into an agreement to acquire The Social Proxy, an AI web data company. Additionally, XTL Biopharmaceuticals has secured $1.5 million in a private placement.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:16 pm

The article highlights the performance of 12 healthcare stocks during Wednesday's after-market session. Notable gainers include SINTX Techs (SINT), Petros Pharma (PTPI), and Bluejay Diagnostics (BJDX). Significant losers include Eyenovia (EYEN), Lucy Scientific Discovery (LSDI), and Monte Rosa Therapeutics (GLUE).

Portfolio Pulse from Benzinga Insights

May 15, 2024 | 8:32 pm

In Friday's pre-market session, health care stocks showed significant movement with Aethlon Medical, Novavax, and Sensus Healthcare leading the gains, while Macrogenics, Progyny, and Protalix BioTherapeutics were among the top losers. The movements were largely driven by the release of Q1 earnings reports.

Portfolio Pulse from Benzinga Insights

May 10, 2024 | 12:07 pm

In Monday's pre-market session, health care stocks showed significant movement. Deciphera Pharmaceuticals led the gainers with a 71.0% increase, while Addex Therapeutics experienced the largest drop, declining by 53.9%. Other notable movers include Koninklijke Philips with a 40.91% increase following their Q1 earnings release, and Cyclacel Pharmaceuticals dropping by 20.53%.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 12:07 pm

Health care stocks showed significant movement in Wednesday's intraday session, with notable gainers including Stoke Therapeutics (STOK) up 46.1% following their Q4 earnings release, and Lixte Biotechnology (LIXT) rising 43.68%. On the losing end, Akili (AKLI) dropped 18.8%, and Mesoblast (MESO) declined by 12.85%. Other companies like Nuvation Bio (NUVB), Ontrak (OTRK), PAVmed (PAVM), and Nutriband (NTRB) also saw substantial gains, while Salarius Pharmaceuticals (SLRX), XTL Biopharmaceuticals (XTLB), Fresh2 Group (FRES), and PDS Biotechnology (PDSB) experienced declines.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 4:31 pm

Landos Biopharma, Inc. (LABP) shares surged over 170% following acquisition news by AbbVie Inc. (ABBV). Other stocks also showed significant movement in Monday's mid-day session, with notable gainers including Next.e.GO N.V. (EGOX), Altamira Therapeutics Ltd. (CYTO), and MicroAlgo Inc. (MLGO), among others. Losers for the day included Sintx Technologies, Inc. (SINT), Akanda Corp. (AKAN), and Fisker Inc. (FSR), with declines attributed to various factors such as public offerings and terminated negotiations.

Portfolio Pulse from Avi Kapoor

March 25, 2024 | 6:44 pm

Health care stocks experienced significant movements in Monday's intraday session. Landos Biopharma's shares surged by 173.9% following their Q4 earnings report. Other notable gainers include Altamira Therapeutics, XTL Biopharmaceuticals, Nkarta, Sagimet Biosciences, and Molecular Templates. On the downside, Trxade Health led the losers with a 48.6% drop, followed by declines in SINTX Techs, Akanda, Invivyd, 180 Life Sciences, and Kineta.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 5:31 pm

In Wednesday's after-market session, several healthcare stocks experienced significant movements. XTL Biopharmaceuticals, Leap Therapeutics, and Jaguar Health were among the top gainers, with increases of 13.9%, 11.21%, and 10.94% respectively. On the downside, Biophytis, Fresh2 Group, and Etao International Co led the losers, with declines of 20.8%, 16.63%, and 14.01% respectively. Notably, Leap Therapeutics' rise followed its Q4 earnings release, and Avinger also reported its Q4 earnings.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 9:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.